Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

The Western New York Chapter of the Alzheimer’s Association will hold an educational program in Salamanca on the common warning signs of Alzheimer’s disease or dementia and the ...

The Western New York Chapter of the Alzheimer’s Association will offer two free programs in the area next week — one on ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) began 2025 with a pair of potentially ...

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

New treatments can slow the disease’s progress, which is why the Alzheimer’s Association is leveraging its celebrity partners ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...